Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Nammi Therapeutics, Inc. (Nammi), a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC) and Nammisome platforms, announces dosing of the first ...

Designed using Daiichi Sankyo's proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in ...

The rest of Plexxikon's pipeline is in early clinical or preclinical ... Pharmaphorum reached out to Daiichi Sankyo to ask for details about the fate of the programmes and Plexxikon's 60-strong ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

The agreement is one of a series of pipeline-boosting deals that MSD ... of three antibody-drug conjugate (ADC) therapies from Daiichi Sankyo for $4 billion upfront in October last year.

Alliance revenues included $361 million from Daiichi Sankyo for Enhertu and $123 million of AstraZeneca ... Backed by its new ...